FSCN1 and neoplasm: First, we determined the effects of the two structurally distinct Fscn1 inhibitors, NP-G2-044 and BDP-13176, on primary splenic DC when applied at a range of concentrations previously reported to confer Fscn1 inhibition in tumor cells (10−6–5 × 10−5 M) [20].